Interview 25 Sep 2018 How to Overcome Failure as a Biotech Company Turning failure into success is a difficult but much needed skill in a high-risk industry such as biotech. At our latest Labiotech Refresh event, Christine Placet, now the CEO of ophthalmic gene therapy company Horama, shared her personal story of how she saved her previous company, Trophos, from an almost certain failure. The mission of […] September 25, 2018 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 11 Sep 2018 How To Break Into The Crowded Immuno-Oncology Space The field of immuno-oncology promises to make anti-cancer treatments more effective than ever. But in this crowded field, many companies struggle to make therapies that not only are effective and safe, but that can also be scaled-up, manufactured and commercialized. Helen Tayton-Martin, Chief Business Officer at the biotech company Adaptimmune, shares her advice on how […] September 11, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 3 Sep 2018 Moving from Big Pharma to Biotech – Insights from Two Biotech CEOs According to John LaMattina in Forbes last year, more and more senior scientific executives are moving from pharma to small biotechs or startup initiatives. While the jury is out on whether this observation reflects a real trend or not, we at Labiotech are keen to learn about what drives people to make such a move! […] September 3, 2018 - 11 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Interview 24 Jul 2018 Meet the Dutch Scientists who Invented Keytruda, “The President’s Drug” Known for curing US President Jimmy Carter’s cancer, Keytruda continues to benefit many other cancer patients. The inventors told us their story, from the drug’s early days to their current role as executives of the biotech unicorn Aduro. Since 2014, the cancer drug Keytruda, also known as pembrolizumab, continues to be widely sought after due […] July 24, 2018 - 6 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
Interview 3 Jul 2018 Fighting Antimicrobial Resistance with Fast Molecular Diagnostics Antimicrobial resistance is predicted to kill more people than cancer by 2050. Is it possible to prevent it? At our Refresh Meetup in Berlin, I talked with Achim Plum, CBO of the diagnostics company Curetis, about what are our best bets to turn the tables in the fight against the threat of antimicrobial resistance. The […] July 3, 2018 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 28 Jun 2018 The Race to Get CRISPR to the Clinic: Hope Versus Hype In 2016, German pharma giant Bayer took a bold step and decided to partner with CRISPR Therapeutics to form a company that could join the race to be first into the clinic with a CRISPR therapy. Peter Nell worked at Bayer for many years and was one of the founding team of Casebia Therapeutics. Now […] June 28, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 22 Jun 2018 Swedish Biotech’s Liquid Biopsy Could Improve Accuracy of Cancer Diagnoses Elypta is developing liquid biopsies that analyze cancer metabolism to make cancer diagnoses more accurate. Philip talked to Francesco Gatto, Elypta’s Chief Scientific Officer and a co-founder, on their technology, moving from academia to industry, and the challenges of starting a biotech company. Even though biotechs and pharma companies across the globe have been pouring […] June 22, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 20 Jun 2018 “Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech Some careers take on an international scope and span the breadth of big players in the pharmaceutical industry and small biotech startups. David Ebsworth, Chairman at Verona Pharma, can count his professional journey among these and gave us the inside scoop on the successes and challenges he faced, his perspective on European biotech, and advice to […] June 20, 2018 - 9 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 13 Jun 2018 CAR-T Brings Hope for Cancer Patients, But Challenges Lie Ahead CAR-T cell therapy has been able to effectively treat cancer in some patients for whom all other treatment options were exhausted. However, the technology still has a long road ahead before becoming a widespread treatment option. Philip spoke to Christian Homsy, CEO of Celyad, at our Refresh Meetup in Brussels about the challenges CAR-T cell […] June 13, 2018 - 5 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 4 Jun 2018 Meet the German Biotech Behind Adidas’ Biodegradable Shoes The synbio company AMSilk is drawing inspiration from nature to produce sustainable materials for applications ranging from clothing to medicine. I spoke to CEO Jens Klein to find out more about the innovative biodegradable material that has caught Adidas’ eye. In 2016, Adidas showed the world the first prototype of a new running shoe that, […] June 4, 2018 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Interview 30 May 2018 How to Close a €3.9B Acquisition Deal for Your Biotech Company Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […] May 30, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Interview 24 May 2018 Sugar-Munching Microbes Put the ‘Eco’ into the Dyeing Industry The commercial dyeing industry is not known for being eco-friendly, which is something that PILI – a synbio startup based in France – is hoping to address with their color producing microbes. Philip chatted with its CEO, Jeremie Blache, to find out more about the company, its recent successful fundraising round and how its technology […] May 24, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email